Defining Optimal Management of Non-metastatic Adrenocortical Carcinoma.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
05 Nov 2023
05 Nov 2023
Historique:
received:
08
06
2023
accepted:
18
10
2023
medline:
5
11
2023
pubmed:
5
11
2023
entrez:
5
11
2023
Statut:
aheadofprint
Résumé
Adrenocortical carcinoma (ACC) is an aggressive, deadly malignancy. Resection remains the primary treatment; however, there is conflicting evidence regarding the optimal approach to and extent of surgery and the role of adjuvant therapy. We evaluated the impact of surgical technique and adjuvant therapies on survival in non-metastatic ACC. We performed a retrospective cohort study of subjects who underwent surgery for non-metastatic ACC between 2010 and 2019 utilizing the National Cancer Database. The primary outcome was overall survival. Cox proportional hazards models were developed to identify associations between clinical and treatment characteristics and survival. Overall, 1175 subjects were included. Their mean age was 54 ± 15 years, and 62% of patients were female. 67% of procedures were performed via the open approach, 22% involved multi-organ resection, and 26% included lymphadenectomy. Median survival was 77.1 months. Age (hazard ratio [HR] 1.019; p < 0.001), advanced stage (stage III HR 2.421; p < 0.001), laparoscopic approach (HR 1.329; p = 0.010), and positive margins (HR 1.587; p < 0.001) were negatively associated with survival, while extent of resection (HR 1.189; p = 0.140) and lymphadenectomy (HR 1.039; p = 0.759) had no association. Stratified by stage, laparoscopic resection was only associated with worse survival in stage III disease (HR 1.548; p = 0.007). Chemoradiation was only associated with improved survival in patients with positive resection margins (HR 0.475; p = 0.004). Tumor biology and surgical margins are the primary determinants of survival in non-metastatic ACC. Surgical extent and lymphadenectomy are not associated with overall survival. In advanced disease, the open approach is associated with improved survival.
Sections du résumé
BACKGROUND
BACKGROUND
Adrenocortical carcinoma (ACC) is an aggressive, deadly malignancy. Resection remains the primary treatment; however, there is conflicting evidence regarding the optimal approach to and extent of surgery and the role of adjuvant therapy. We evaluated the impact of surgical technique and adjuvant therapies on survival in non-metastatic ACC.
METHODS
METHODS
We performed a retrospective cohort study of subjects who underwent surgery for non-metastatic ACC between 2010 and 2019 utilizing the National Cancer Database. The primary outcome was overall survival. Cox proportional hazards models were developed to identify associations between clinical and treatment characteristics and survival.
RESULTS
RESULTS
Overall, 1175 subjects were included. Their mean age was 54 ± 15 years, and 62% of patients were female. 67% of procedures were performed via the open approach, 22% involved multi-organ resection, and 26% included lymphadenectomy. Median survival was 77.1 months. Age (hazard ratio [HR] 1.019; p < 0.001), advanced stage (stage III HR 2.421; p < 0.001), laparoscopic approach (HR 1.329; p = 0.010), and positive margins (HR 1.587; p < 0.001) were negatively associated with survival, while extent of resection (HR 1.189; p = 0.140) and lymphadenectomy (HR 1.039; p = 0.759) had no association. Stratified by stage, laparoscopic resection was only associated with worse survival in stage III disease (HR 1.548; p = 0.007). Chemoradiation was only associated with improved survival in patients with positive resection margins (HR 0.475; p = 0.004).
CONCLUSION
CONCLUSIONS
Tumor biology and surgical margins are the primary determinants of survival in non-metastatic ACC. Surgical extent and lymphadenectomy are not associated with overall survival. In advanced disease, the open approach is associated with improved survival.
Identifiants
pubmed: 37925657
doi: 10.1245/s10434-023-14533-w
pii: 10.1245/s10434-023-14533-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94(6):1853–78.
doi: 10.1210/jc.2008-2291
pubmed: 19494161
pmcid: 5393375
Sharma E, Dahal S, Sharma P, Bhandari A, Gupta V, Amgai B, Dahal S. The characteristics and trends in adrenocortical carcinoma: a United States population based study. J Clin Med Res. 2018;10(8):636.
doi: 10.14740/jocmr3503w
pubmed: 29977421
pmcid: 6031252
Kebebew E, Reiff E, Duh Q-Y, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress? World J Surg. 2006;30(5):872–8.
doi: 10.1007/s00268-005-0329-x
pubmed: 16680602
Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer. 1993;72(11):3145–55.
doi: 10.1002/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N
pubmed: 8242539
Luton J-P, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322(17):1195–201.
doi: 10.1056/NEJM199004263221705
pubmed: 2325710
Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009;23(2):273–89.
doi: 10.1016/j.beem.2008.10.008
pubmed: 19500769
Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282–326.
doi: 10.1210/er.2013-1029
pubmed: 24423978
Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma: clinical outcome at the end of the 20th century. Cancer. 2001;92(5):1113–21.
doi: 10.1002/1097-0142(20010901)92:5<1113::AID-CNCR1428>3.0.CO;2-I
pubmed: 11571723
Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113(11):3130–6.
doi: 10.1002/cncr.23886
pubmed: 18973179
Datta J, Roses RE. Surgical management of adrenocortical carcinoma: an evidence-based approach. Surg Oncol Clin. 2016;25(1):153–70.
doi: 10.1016/j.soc.2015.08.011
Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122(6):1212–8.
doi: 10.1016/S0039-6060(97)90229-4
pubmed: 9426440
Porpiglia F, Fiori C, Daffara F, et al. Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome? J Endocrinol Investig. 2016;39(4):465–71.
doi: 10.1007/s40618-015-0422-4
Porpiglia F, Fiori C, Daffara F, Zaggia B, Scarpa RM, Terzolo M. Does nephrectomy during radical adrenalectomy for adrenocortical cancer affect oncological results? J Urol. 2010;183(4S):e11–e11.
doi: 10.1016/j.juro.2010.02.069
Marincola Smith P, Kiernan CM, Tran TB, et al. Role of additional organ resection in adrenocortical carcinoma: analysis of 167 patients from the US adrenocortical carcinoma database. Ann Surg Oncol. 2018;25:2308–15.
doi: 10.1245/s10434-018-6546-y
pubmed: 29868977
Gaujoux S, Brennan MF. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery. 2012;152(1):123–32.
doi: 10.1016/j.surg.2011.09.030
pubmed: 22306837
Hendricks A, Müller S, Fassnacht M, Germer C-T, Wiegering VA, Wiegering A, Reibetanz J. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma: a systematic review and meta-analysis. Cancers. 2022;14(2):291.
doi: 10.3390/cancers14020291
pubmed: 35053453
pmcid: 8774191
Jasim S, Habra MA. Management of adrenocortical carcinoma. Curr Oncol Rep. 2019;21(3):1–11.
doi: 10.1007/s11912-019-0773-7
Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372–80.
doi: 10.1056/NEJMoa063360
pubmed: 17554118
Boffa DJ, Rosen JE, Mallin K, et al. Using the national cancer database for outcomes research: a review. JAMA Oncol. 2017;3(12):1722–8.
doi: 10.1001/jamaoncol.2016.6905
pubmed: 28241198
Mallin K, Browner A, Palis B, et al. Incident cases captured in the National Cancer Database compared with those in US population based central cancer registries in 2012–2014. Ann Surg Oncol. 2019;26(6):1604–12.
doi: 10.1245/s10434-019-07213-1
pubmed: 30737668
Reibetanz J, Jurowich C, Erdogan I, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255(2):363–9.
doi: 10.1097/SLA.0b013e3182367ac3
pubmed: 22143204
Gerry JM, Tran TB, Postlewait LM, et al. Lymphadenectomy for adrenocortical carcinoma: Is there a therapeutic benefit? Ann Surg Oncol. 2016;23(5):708–13.
doi: 10.1245/s10434-016-5536-1
pubmed: 27590329
pmcid: 5257294
Saade N, Sadler C, Goldfarb M. Impact of regional lymph node dissection on disease specific survival in adrenal cortical carcinoma. Horm Metab Res. 2015;47(11):820–5.
doi: 10.1055/s-0035-1549877
pubmed: 25938888
Stata Statistical Software. Release 17 [computer program]. College Station: StataCorp LLC; 2021.
Ginsburg KB, Chandra AA, Handorf EA, et al. Association of surgical approach with treatment burden, oncological effectiveness, and perioperative morbidity in adrenocortical carcinoma. Clin Genitourin Cancer. 2022;20(5):497.e491-497.
doi: 10.1016/j.clgc.2022.04.011
Shah M, NeMoyer RE, Kashyap R, et al. Surgical resection for adrenocortical carcinoma: current trends affecting survival. J Surg Oncol. 2022;125:1224–30.
doi: 10.1002/jso.26845
pubmed: 35286718
Tseng J, DiPeri T, Chen Y, et al. Adrenocortical carcinoma: the value of lymphadenectomy. Ann Surg Oncol. 2022;29(3):1965–70.
doi: 10.1245/s10434-021-11051-5
pubmed: 34792698
Hue JJ, Ahorukomeye P, Bingmer K, et al. A comparison of robotic and laparoscopic minimally invasive adrenalectomy for adrenal malignancies. Surg Endosc. 2022;36(7):5374–81.
doi: 10.1007/s00464-021-08827-x
pubmed: 34724582
Delman AM, Turner KM, Griffith A, Schepers E, Ammann AM, Holm TM. Minimally invasive surgery for resectable adrenocortical carcinoma: a nationwide analysis. J Surg Res. 2022;279:200–7.
doi: 10.1016/j.jss.2022.04.078
pubmed: 35780533
Lee J, El-Tamer M, Schifftner T, et al. Open and laparoscopic adrenalectomy: analysis of the national surgical quality improvement program. J Am Coll Surg. 2008;206(5):953–9.
doi: 10.1016/j.jamcollsurg.2008.01.018
pubmed: 18471733
Yip L, Duh Q-Y, Wachtel H, et al. American association of endocrine surgeons guidelines for adrenalectomy: executive summary. JAMA Surg. 2022;157(10):870–7.
doi: 10.1001/jamasurg.2022.3544
pubmed: 35976622
pmcid: 9386598
Fassnacht M, Dekkers OM, Else T, et al. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2018;179(4):G1–46.
doi: 10.1530/EJE-18-0608
pubmed: 30299884